Loudoun Medical Group, P.C. v. Michael S. Barnes

CourtCourt of Appeals of Virginia
DecidedApril 22, 2025
Docket0051244
StatusUnpublished

This text of Loudoun Medical Group, P.C. v. Michael S. Barnes (Loudoun Medical Group, P.C. v. Michael S. Barnes) is published on Counsel Stack Legal Research, covering Court of Appeals of Virginia primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Loudoun Medical Group, P.C. v. Michael S. Barnes, (Va. Ct. App. 2025).

Opinion

COURT OF APPEALS OF VIRGINIA UNPUBLISHED

Present: Judges O’Brien, Ortiz and Lorish Argued at Fredericksburg, Virginia

LOUDOUN MEDICAL GROUP, P.C. MEMORANDUM OPINION* BY v. Record No. 0051-24-4 JUDGE MARY GRACE O’BRIEN APRIL 15, 2025 MICHAEL S. BARNES

FROM THE CIRCUIT COURT OF LOUDOUN COUNTY James P. Fisher, Judge

Elaine D. McCafferty (Elizabeth Guilbert Perrow; Daniel T. Sarrell; Woods Rogers Vandeventer Black PLC, on briefs), for appellant.

Benjamin M. Wengerd (Travis W. Markley; Richard L. Nagle; TrialHawk Litigation Group, LLC, on brief), for appellee.

Loudoun Medical Group, P.C., (LMG) appeals a jury verdict for Michael Barnes in a

medical malpractice suit. LMG argues that the circuit court erred in denying its motion for a

mistrial or continuance after its lead counsel suffered a heart attack. LMG further contends that the

court erred in allowing Barnes’s causation expert to give standard-of-care testimony and in

excluding evidence about Barnes’s liver transplant medication.

BACKGROUND

On appeal of a court’s decision to sustain a jury verdict, we review the evidence “in the light

most favorable to the plaintiff.” Boyd v. Weisberg, 75 Va. App. 725, 736 (2022) (quoting Ferguson

Enters., Inc. v. F.H. Furr Plumbing, Heating & Air Conditioning, Inc., 297 Va. 539, 548 (2019)).

In 1999, Barnes received a liver transplant due to an autoimmune disease. In February

2020, he sought treatment for knee pain, for which physician assistant (PA) Reena Patel, an

* This opinion is not designated for publication. See Code § 17.1-413(A). employee of LMG, prescribed diclofenac,1 a nonsteroidal anti-inflammatory (NSAID). Barnes

subsequently became jaundiced and fatigued, but Patel did not monitor his liver functions. Barnes

experienced liver failure in April 2020, which required hospitalization and placement on a liver

transplant list.

Barnes brought a medical malpractice action against LMG, alleging that Patel breached the

standard of care by prescribing diclofenac.2 LMG filed an answer and a demurrer, which was

overruled. LMG later moved to amend its answer to raise contributory negligence as an affirmative

defense. The court did not rule on the motion to amend before trial.

A. Trial

At trial, LMG was represented by two attorneys from the same law firm—Coreen Silverman

and Kelvin Newsome. Newsome delivered LMG’s opening statement, outlining in detail the

evidence and witnesses that LMG planned to present.

Barnes began his case by playing Patel’s video deposition for the jury. In it, Patel testified

she was aware of Barnes’s prior liver transplant, but it did not affect her decision to prescribe

diclofenac because she was not aware of any “contraindication to prescribing an NSAID” or any

“special risk factors associated with hepatotoxicity for diclofenac.” Patel also stated that she had

reviewed the FDA label before writing the prescription. She acknowledged that she did not monitor

Barnes’s liver functions during follow-up appointments.

Barnes’s wife testified that her husband had fully recovered after his liver transplant in 1999.

She also stated that Barnes takes tacrolimus, an anti-rejection medication, “as it is prescribed.”

1 Diclofenac is also known by the brand name Voltaren.

Barnes initially sued Patel, Dr. Matthew Gavin (Patel’s supervisor), and LMG, d/b/a 2

Leesburg Orthopedics, but later nonsuited Patel and Dr. Gavin. -2- 1. Exclusion of Evidence Disputing Tacrolimus Compliance

On the second day of trial, Barnes moved to exclude evidence concerning contributory

negligence based on noncompliance with his tacrolimus prescription. He argued that LMG had

effectively withdrawn this affirmative defense because it never sought a ruling on its motion to

amend its answer. LMG responded that it was waiting until “there’s evidence to support the

contributory negligence” and asserted that the court should allow evidence of Barnes’s failure to

take tacrolimus. Barnes in turn contended that he lacked notice because contributory negligence

was not properly pleaded. The court acknowledged that LMG had referred to contributory

negligence during its opening but agreed with Barnes and “prohibit[ed] further references to fact[s]

or circumstances that amount to an allegation of contributory negligence.” LMG nevertheless

insisted that evidence concerning Barnes’s compliance with this tacrolimus prescription was

relevant to causation, not contributory negligence. Finding that LMG’s goal was to show

contributory negligence “regardless of what you call it,” the court rejected the causation argument.

LMG did not proffer any evidence of Barnes’s failure to take tacrolimus as prescribed.

2. Barnes’s Standard-of-Care and Causation Experts

Dr. Jeffrey Meisels testified for Barnes as an expert witness on the standard of care.

Dr. Meisels, who has practiced since 1987, concluded that Patel’s care fell below the standard

because Barnes’s prior liver transplant was a complex medical issue that required familiarity with

the properties of prescribed medications. He explained that if he had a liver transplant patient, he

“wouldn’t prescribe any NSAID for them” and “in particular, diclofenac,” because it has the highest

incidents of causing liver issues. He continued that merely reading the “black box warnings

section3 and the contraindication section” of the FDA prescription information fell below the

3 Black box warnings are black outlines on FDA medication guides to draw attention to possible serious complications or contraindications. -3- standard of care. Further, the FDA’s document explained diclofenac’s metabolization and reported

incidents of “drug-induced hepatotoxicity.” Dr. Meisels testified that Patel’s failure to tell Barnes of

the risks and symptoms of hepatotoxicity also showed a failure to meet the standard of care.

Having reviewed Patel’s deposition, Dr. Meisels concluded that Patel did not know that

“diclofenac carried a risk of hepatotoxicity” and therefore prescribing it fell below the standard of

care. Newsome was the LMG attorney who conducted the cross-examination of Dr. Meisels.

PA Lawrence Collins, a practitioner with 33 years’ experience, testified as Barnes’s second

standard-of-care expert. He opined that Patel’s actions fell below the standard of care because

diclofenac is metabolized by the liver, increasing risk of liver injury, which “should be common

knowledge for any PA” because it is part of a PA’s education. Collins concluded that because Patel

had been unaware of diclofenac’s risks, she breached the standard of care by prescribing it.

On the third day of trial, Barnes called Dr. Halegoua-DeMarzio, a transplant hepatologist

with 16 years of experience, as an expert on causation, damages, and drug-induced liver injuries.

She explained the unique risks associated with diclofenac and testified that diclofenac could cause

an autoimmune reaction in the liver and lead to liver failure. Then the following exchange

occurred:

Q: Even if [serious liver injury from diclofenac is] rare, is it serious enough to dissuade you from recommending diclofenac to a patient?

A: Yes. In a medication that’s not necessary, there -- you know, it’s just a pain medicine, -- there are other pain medicine options. You would never take this risk that potentially could honestly kill a patient. It’s not worth it.

(Emphasis added).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Grattan v. Com.
685 S.E.2d 634 (Supreme Court of Virginia, 2009)
Zelnick v. Adams
606 S.E.2d 843 (Supreme Court of Virginia, 2005)
Hinkley v. Koehler
606 S.E.2d 803 (Supreme Court of Virginia, 2005)
Lowe v. Cunningham
601 S.E.2d 628 (Supreme Court of Virginia, 2004)
Keesee v. Donigan
524 S.E.2d 645 (Supreme Court of Virginia, 2000)
Cephas Leon Blunt v. Commonwealth of Virginia
741 S.E.2d 91 (Court of Appeals of Virginia, 2013)
Wright v. Commonwealth
667 S.E.2d 787 (Court of Appeals of Virginia, 2008)
Tynes v. Commonwealth
635 S.E.2d 688 (Court of Appeals of Virginia, 2006)
Molina v. Commonwealth
624 S.E.2d 83 (Court of Appeals of Virginia, 2006)
Perez v. Commonwealth
580 S.E.2d 507 (Court of Appeals of Virginia, 2003)
Durant v. Commonwealth
546 S.E.2d 216 (Court of Appeals of Virginia, 2001)
McGee v. Commonwealth
487 S.E.2d 259 (Court of Appeals of Virginia, 1997)
Spence v. Miller
90 S.E.2d 131 (Supreme Court of Virginia, 1955)
Swersky v. Higgins
76 S.E.2d 200 (Supreme Court of Virginia, 1953)
Gene Anthony Brown v. Commonwealth of Virginia
764 S.E.2d 297 (Court of Appeals of Virginia, 2014)
Jason N. Creamer v. Commonwealth of Virginia
767 S.E.2d 226 (Court of Appeals of Virginia, 2015)
Du v. Commonwealth
790 S.E.2d 493 (Supreme Court of Virginia, 2016)
Justo Mazariegos Campos v. Commonwealth of Virginia
800 S.E.2d 174 (Court of Appeals of Virginia, 2017)
Leroy Ellis v. Commonwealth of Virginia
813 S.E.2d 16 (Court of Appeals of Virginia, 2018)
Campbell v. Campbell
642 S.E.2d 769 (Court of Appeals of Virginia, 2007)

Cite This Page — Counsel Stack

Bluebook (online)
Loudoun Medical Group, P.C. v. Michael S. Barnes, Counsel Stack Legal Research, https://law.counselstack.com/opinion/loudoun-medical-group-pc-v-michael-s-barnes-vactapp-2025.